T1	Participants 113 172	operable breast cancer with 0 to 3 positive axillary nodes:
T2	Participants 405 430	metastatic breast cancer.
T3	Participants 545 568	operable breast cancer.
T4	Participants 590 738	Women with invasive breast cancer were eligible if there were one to three positive lymph nodes or if the node-negative tumor was greater than 1 cm.
T5	Participants 739 784	Patients were randomly assigned after surgery
T6	Participants 967 1054	patients with estrogen receptor (ER) and/or progesterone receptor (PR)-positive tumors.
T7	Participants 1074 1107	2,882 eligible patients enrolled.
